Last reviewed · How we verify
Unisol
Unisol is a Small molecule drug developed by Deacon Biosciences, Inc.. It is currently in Phase 2 development.
Unisol is a treatment used in clinical trials for conditions such as ocular infection, dry eye syndrome, and corneal staining. It has been compared to DCN01 and Systane Ultra Lubricant Eye Drops in studies assessing its anti-microbial efficacy and safety.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Unisol |
|---|---|
| Sponsor | Deacon Biosciences, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Daily Irrigation With Silicone Hydrogel Contact Lens Continuous Wear (PHASE4)
- A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers (PHASE2)
- Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline (NA)
- Assessment of Tear Film-Based Proteins Associated With Care Solution Induced Corneal Staining (NA)
- Residence Time Evaluation of Marketed OTC Ophthalmic Products (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Unisol CI brief — competitive landscape report
- Unisol updates RSS · CI watch RSS
- Deacon Biosciences, Inc. portfolio CI
Frequently asked questions about Unisol
What is Unisol?
Who makes Unisol?
What development phase is Unisol in?
Related
- Manufacturer: Deacon Biosciences, Inc. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing